RVMD News
Archived Headlines
- US IPO Week Ahead: IPO market hits February lull in 2-IPO week 02/07/20
- Oncology biotech Revolution Medicines sets terms for $150 million IPO 02/03/20
- US IPO Weekly Recap: 3 Chinese companies and a mortgage lender kick off the 2020 US IPO market 01/17/20
- Oncology biotech Revolution Medicines files for a $100 million IPO 01/17/20
US IPO Week Ahead: The IPO market takes a breather in a 4 IPO week
Updated Monday, 8/10 After an active July, the US IPO market is taking a breather. Three companies are scheduled to raise $2.5 billion in the week ahead, led by Chinese real estate giant KE Holdings (BEKE). KE Holdings (BEKE), China's largest...read more
US IPO Weekly Recap: The year's busiest slow week?
Six companies and five SPACs entered the public market raising about $2 billion. The week's deals mostly included uplistings, crosslistings, and micro-caps, with biotech Revolution Medicines (RVMD) soaring in the standout IPO of the week. Luxury...read more
Oncology biotech Revolution Medicines prices IPO at $17, the high end of the revised range
Revolution Medicines, a Phase 1/2 oncology biotech developing RAS pathway inhibitors, raised $238 million by offering 14 million shares at $17, the high end of the range of $16 to $17. The company originally filed to offer 10 million shares at a range of $14 to ...read more
Oncology biotech Revolution Medicines raises IPO range to $16 to $17 with market cap set to exceed $1 billion
Revolution Medicines, a Phase 1/2 oncology biotech developing RAS pathway inhibitors, raised the proposed deal size for its upcoming IPO on Tuesday. The Redwood City, CA-based company now plans to raise $231 million by offering 14 million shares at a price...read more